ClinicalTrials.gg
RecruitingNCT06754605Updated Feb 13, 2025

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine

A Phase 1/2 interventional study of SCTV02 and Placebo in Respiratory Syncytial Virus, sponsored by Sinocelltech Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 120 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-13.

Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Study summary

This is a randomised, double-blind, placebo-controlled Phase 1/2 clinical trial to evaluate the safety, tolerability and immunogenicity of recombinant respiratory syncytial virus in participants aged 18 years and older.

Read the detailed description

Three dose-levels of SCTV02 will be evaluated in participants aged 18 years and older. Solicited adverse events within 7 days post study vaccination and unsolicited adverse events within 30 days post study vaccination will be collected. Immunogenicity including Neutralizing antibody against RSV-A and RSV-B will be tested 14, 30, 90, 180 and 365 days post study vaccination will be assessed. T cell response will be tested 30 days post study vaccination.

02

Conditions studied

  • Respiratory Syncytial Virus
03

In context

Lead sponsor

Sinocelltech Ltd. is the lead sponsor of 82 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Phase I: male and female participants ≥18 years old at the time of signing the ICF; Phase II: male and female participants ≥50 years of age at the time of signing the ICF.
  • Be able to sign a written form (ICF) and participate in the trial voluntarily, and can fully understand the trial procedures and risks of participating in the trial.
  • Be able to complete the diary card, contact card and diary/contact card by own or with the assistance of others.
  • Phase I: healthy subjects or healthy subjects judged by the investigator according to the clinical data of the subjects; Stage II: Subjects who are healthy or have a stable underlying disease.
  • Fertile men and women of childbearing age voluntarily agree to use effective from the time they sign the ICF until 6 months after immunization; Pregnancy test results for women of childbearing age during the screening period were negative.

Exclusion criteria

Exclusion Criteria:

  • Acute illness and/or fever (axillary temperature ≥37.3 ° C) occurred within 3 days prior to vaccination with the study vaccine, or antipyretic, analgesic, or antiallergic drugs.
  • Use any or unregistered product within 30 days prior to immunization, or plan to use any such product during the study period.
  • Concurrent participation in another clinical study where the subject has been or will be exposed to an investigational or non-investigational vaccine/product at any time during the study.
  • Long-term or high-dose therapy (duration ≥15 days, or dose ≥1 mg/kg/ day of prednisone or equivalent doses of other glucocorticoids), or other and cytotoxic therapy within 90 days prior to vaccination.
  • The study received a non-attenuated vaccine within 14 days prior to vaccination, or a within 28 days; Have previously received the experimental respiratory syncytial virus (RSV) vaccine or been infected with RSV within 1 year prior to receiving the investigational vaccine.
  • History or family history of epilepsy and mental illness.
  • A family history of congenital or hereditary immunodeficiency, or a history and physical examination confirmed or suspected immunosuppression or immunodeficiency, or (HIV) infection, asplenia or functional asplenia.
  • Have the following organ-specific or systemic diseases: Guillain-Barre syndrome, myasthenia gravis, autoimmune hepatitis, ulcerative colitis, systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, and systemic sclerosis.
  • Allergic to any component of the study vaccine, or any previous history of severe allergy to vaccine vaccination, such as anaphylactic shock, allergic laryngeal edema, anaphylactoid purpura, thrombocytopenic purpura, local allergic necrosis reaction, angioneurotic edema, etc.
  • Severe chronic disease or active chronic disease, as assessed by the investigator, including but not limited to myocardial infarction, severe arrhythmia, unstable angina, uncontrolled blood pressure after medication (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg in subjects \< 60 years of age; Hypertensive disease with systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg in subjects ≥60 years of age, diabetes mellitus with serious complications, cancer or precancerous lesions, and other serious cerebrovascular diseases, heart diseases, respiratory diseases, liver and kidney diseases, and thyroid diseases.
  • Pregnant women (positive pregnancy test) or breastfeeding women, or those with pregnancy plans during the study period, or less than 6 weeks after the end of pregnancy (including ectopic pregnancy).

Plan to donate eggs or sperm during the study.

  • Unable to follow the trial procedures, or plan to relocate or stay away for a long period of time during the study and cannot complete the trial follow-up.
  • Any medical condition that makes intramuscular injection unsafe due to other abnormalities, conditions that may obfuscate the results of the study, or conditions that are not in the best interest of the subject, is determined by the investigator to be unsuitable for clinical study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
480 participants (estimated)

Study arms

  • Experimental
    A: Low dose vaccine

    Low dose of SCTV02, injected on Day 0

    Biological: SCTV02

  • Placebo comparator
    A: Low dose placebo

    Placebo comparator of low dose, injected on Day 0

    Biological: Placebo

  • Experimental
    B: Medium dose vaccine

    Medium dose of SCTV02, injected on Day 0

    Biological: SCTV02

  • Placebo comparator
    B: Medium dose placebo

    Placebo comparator of medium dose, injected on Day 0

    Biological: Placebo

  • Experimental
    C: High dose vaccine

    High dose of SCTV02, injected on Day 0

    Biological: SCTV02

  • Placebo comparator
    C: High dose placebo

    Placebo comparator of high dose, injected on Day 0

    Biological: Placebo

  • Experimental
    D: Low dose vaccine

    Low dose of SCTV02, injected on Day 0

    Biological: SCTV02

  • Experimental
    E: Medium dose vaccine

    Medium dose of SCTV02, injected on Day 0

    Biological: SCTV02

  • Experimental
    F: High dose vaccine

    High dose of SCTV02, injected on Day 0

    Biological: SCTV02

  • Placebo comparator
    G: Placebo

    Placebo comparator, injected on Day 0

    Biological: Placebo

Interventions

  • BiologicalSCTV02

    Participants will receive a singe dose of SCTV02 on Day 0.

  • BiologicalPlacebo

    Participants will receive a singe dose of Placebo on Day 0.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of solicited adverse events within 7 days post study vaccination.

    Incidence and severity of solicited adverse events within 7 days post study vaccination.

    Time frame: Day o to Day 7

  2. Geometric mean titer (GMT) of neutralizing antibodies (nAb) against RSV-A and RSV-B subtypes 30 days post vaccination

    Geometric mean titer (GMT, Live Virus Neutralization Test) of neutralizing antibodies (nAb) against RSV-A and RSV-B subtypes 30 days after study vaccination.

    Time frame: Day 30

Secondary outcomes

  1. GMT of nAb against RSV-A and RSV-B subtypes 14 days after study vaccination.Immunogenicity 14 days post vaccination

    GMT of nAb against RSV-A and RSV-B subtypes 14 days after study vaccination.

    Time frame: Day 14

  2. GMT of nAb against RSV-A and RSV-B subtypes 90 days post vaccination

    GMT (Live Virus Neutralization Test) of neutralizing antibodies (nAb) against RSV-A and RSV-B subtypes 90 days after study vaccination.

    Time frame: Day 90

  3. GMT of nAb against RSV-A and RSV-B subtypes 180 days post vaccination

    GMT (Live Virus Neutralization Test) of neutralizing antibodies (nAb) against RSV-A and RSV-B subtypes 180 days after study vaccination.

    Time frame: Day 180

  4. GMT of nAb against RSV-A and RSV-B subtypes 365 days post vaccination

    GMT (Live Virus Neutralization Test) of neutralizing antibodies (nAb) against RSV-A and RSV-B subtypes 365 days after study vaccination.

    Time frame: Day 365

  5. T cell response

    Number of T cell subsets activated by interferon-γ (for Th1) and interleukin-4 (for Th2) 30 days after study vaccination.

    Time frame: Day 30

  6. Incidence and severity of unsolicited adverse events within 30 days

    Incidence and severity of unsolicited adverse events within 30 days after study vaccination.

    Time frame: Day to Day 30

  7. Incidence and severity of Serious adverse events and adverse events of special interest within 365 days

    Incidence and severity of Serious adverse events and adverse events of special interest within 365 days after study vaccination.

    Time frame: Day 0 to Day 365

07

Study locations

1 of 2 sites recruiting
  • Hebei Zhongshiyou Central Hospital
    Langfang, Hebei 965000, China
    Recruiting
    • Zhao Kexin, Doctor · Contact86-0316-2073657
  • Luzhou Center for Disease Control and Prevention
    Luzhou, Sichuan 646399, China
    Not yet recruiting
    • He Wenlin, Doctor · Contact86-0830-2584041
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Jul 2027, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2024
First posted
Jan 1, 2025
StartActual
Feb 6, 2025
Primary completionEst.
Jul 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Feb 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06754605
Lead sponsor
Sinocelltech Ltd.
Responsible party
Sponsor
First posted
Jan 1, 2025
Start date
Feb 6, 2025
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Feb 13, 2025

Study contacts

Yang Xinjie, Doctor
Contact
xinjie_yang@sinocelltech.com
86+010-58628288
Zhao Kexin, Doctor
principal investigator · Hebei Zhongshiyou Central Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion